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Glossary
A brief explanantion of some key terms and abbreviations that appear in 
the text.
Civil society: can be thought of as the associational life operating in the 
space between the state and the market – that is, not the public sector and 
not the private sector. Typically, it is understood to include the activities of 
non-governmental, voluntary and community organisations, but can also 
include individual participation. 
CND: Commission on Narcotic Drugs
CSFD: Civil Society Forum on Drugs
CSOs:  Civil society organisations;  those organisations operating in civil 
society.
CSI: Civil society invovement; the process or practice of including civil 
society in policy development, setting and implementation.
CSIDP: Civil Society Involvement in Drug Policy
EMCDDA: European Monitoring Centre for Drugs and Drug Addiction
EU: European Union
HIV / AIDS: Human Immunodeficiency Virus / Acquired Immunodeficiency 
Syndrome
Policy makers:  The people who decide the state’s course of action in 
any given jurisdiction or policy arena. Typically, the group includes elected 
representatives, particularly those with responsibility for certain portfolios, 
but can also include civil and public servants when aspects of policy 
delivery are devolved fromthe political.
PWUD: People who use drugs
UNGASS: United Nations General Assembly Special Session
UNAIDS: Joint United Nations Programme on HIV/AIDS
WHO: World Health Organisation
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The inclusion of civil society in the development 
and implementation of drug policies is widely 
recognised as being critically important. Civil 
society input can provide added context to 
policy considerations, giving policy makers 
access to a greater range of insights and 
information, and can support the popular 
legitimacy of policy actions. In short, a 
structured and formal civil society involvement 
(CSI) in policy arenas can better equip states 
to plan, implement and measure policy 
initiatives, thus directly contributing to national 
and EU drugs strategy objectives. However, 
states and civil society organisations (CSOs) do 
not always have ready access to good quality 
information on how this can be best achieved. 
This is the challenge that this document is 
directed at assisting with. This is a ‘Road Map’ 
for civil society involvement in drug policy. It 
is directed at both policy makers and CSOs, 
and its main objective is to provide guidance 
through the different steps of developing and 
implementing effective and sustainable civil 
society structures in the field of drug policy 
on the local, regional and national level, as 
informed by the best available evidence. It is 
hoped that CSOs and policy makers will find it 
useful in planning and developing CSI in their 
countries. 
Following this brief introduction, and a brief 
note on why CSI is important, the Road Map is 
broken into three parts.
PART 1 looks at how to assess current levels 
of CSI in drug policy. In order to improve, it is 
first important to know where we are. Thus, 
the first step towards enhancing CSI is to 
assess its status quo on the policy level or drug 
policy field of interest and to identify where 
improvement is needed. Part 1 covers the 
process of implementing such an assessment. 
PART 2 looks at what can be done on the side 
of the policymakers to enhance CSI – from 
implementing different mechanisms of CSI to 
funding CSOs and research.
PART 3 looks at what can be done on the side 
of CSOs to enhance CSI - from addressing 
possible structural issues to planning advocacy 
activities.  
In each part, short practical examples are 
provided to illustrate key points. For those 
interested in more details, more comprehensive 
examples are available on the CSIDP website 
– www.csidp.eu Furthermore, for all the steps 
of the Road Map, external links are provided 
which will lead you to existing guidelines, 
toolkits and further information on these topics. 
This Road Map was developed in the framework 
of the project “Civil Society Involvement in 
Drug Policy” which is co-financed by the 
European Union. For more information on the 
project, please see www.csidp.eu.
Introduction
There are many reasons as to why the inclusion of Civil Society Organisations 
(CSOs) in the processes of developing and implementing drug policy should 
be promoted. By improving levels of Civil Society Involvement (CSI) in these 
processes, a range of benefits result for all parties involved. Before looking 
at these benefits, it is important to note that not only is CSI desirable, it is 
also necessary. On a fundamental level,  and according to the European 
Convention of Human Rights (ECHR), citizens have freedoms of expression 
(Art.10) and of assembly and association (Art. 11). The Pompidou Group 
(2016) has recognised these rights as providing the foundation for CSI, 
noting both that “all citizens have the right to make their opinions known 
and are allowed to form, support and join political parties and pressure 
movements to effectively enjoy their rights to make their political thoughts 
known”, and that “[c]ivil society involvement in policy planning and 
delivery is an obligation in a democratic society”.1 As noted earlier, CSI is 
a necessity and, moreover, it brings with it multiple benefits. Some of these 
are set out below. 
One of the key benefits of a strong and involved civil society is that it can 
bring new information to decision-makers in a variety of ways, including 
through research, experience working in close contact with particular 
populations and through bringing diverse opinions and ideas2. Thus, 
civil society involvement can allow early identification and anticipation 
of problems and trends. Similarly, the Pompidou Group (2016) notes that 
Civil Society Organisations (CSOs) bring “knowledge and independent 
expertise to the process of decision making and policy making”.3 CSI 
allows both politics and civil society to break out of simplistic frameworks, 
such as those of the state or the market and explore new possibilities4. 
These factors are important – civil society input can provide contingency, 
giving policy makers different options for action.
Thus, improvement of the processes in which CSOs can become involved 
in drug policy will result in the opening of a channel of communication 
between those who work in the field and the policymakers. This can add 
to policymakers’ understanding of an ‘on the ground’ environment which 
is often in flux. Greer et al (2017) note that civil society delivers things that 
state, market and family cannot deliver5, and that working to increase 
Why improve civil society involvement in drug policy? 
Marcus Keane & Lauren Crook
 1Pompidou Group (2016). 
Policy paper on government 
interaction with civil society on 
drug policy issues. Principles, 
ways and means, opportunities 
and challenges. p.1.
2 See, for example,  
Greer, S., Wismar, M. and 
Kosinska, M. (2017). 
What is civil society and 
what can it do for health? 
In: S. Greer, M. Wismar, G. 
Pastorino and M. Kosinska, 
ed., Civil Society and health - 
contributions and potential. 
[online] World Health 
Organisation, pp.15-16. 
Available at: http://www.euro.
who.int/__data/assets/pdf_
file/0011/349526/Civil-society-
web-back-cover-updated.
pdf?ua=1 
[Accessed 22 Feb. 2018].
3 Ibid., p.1
4 Greer, Wismar and Kosinska 
(2017), p.6
5 Greer, Wismar and Kosinska 
(2017), p. 14
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communication between these areas will allow policymakers to benefit 
from CSO experience, permitting policy to be informed by those who 
are most familiar with the daily realities of working under existing policy 
structures. Additionally, research from other policy arenas indicates that 
good CSI can create a better acceptance of policies – when civil society 
is involved, popular legitimacy increases6. The process can be perceived 
as more transparent and accountable – important features of good 
governance. As the Pompidou Group (2016) has noted, CSI creates added 
value to the policy and planning process itself, ‘enhancing the legitimacy, 
quality, and understanding and longer-term applicability of the policy 
initiative’.7 Thus, a structured and formal CSI can better equip states to 
plan, implement and measure policy initiatives, thus directly contributing 
to national and EU drugs strategy objectives. 
CSOs also have an important role to play in networking – providing 
extesive contacts, platforms and other mechanisms for cooperation on 
local national and international level. As the Pompidou Group (2016) have 
noted, ‘[b]y making use of information and communication technology, 
this constitutes a resource of infinite opportunities’.8
Nonetheless, CSOs currently may have limited impact on a policy-making
level. Potential reasons for this include a lack of knowledge of the structures 
needed to become meaningfully involved (or a lack of accessible 
An example of good practice of CSI in national drug policy: 
The decision-making process in Portugal
The Commission for the National Strategy to Fight Against Drugs was established in 1998, 
constituted by a pool of experts from different backgrounds and fields of intervention. At 
the time, the National Strategy integrated in a very participative way the contributions of 
several representatives of the community, namely PWUD, their families, professionals from 
the schools, the health structures, the courts, the neighbourhoods, etc. In April 1999 the 
National Strategy was approved, stating in the law some fundamental principles, among 
which must be highlighted “the principle of participation”, referring the participation of 
community in the definition of drug policies and in its further involvement in the intervention 
strategies. The Portuguese Drug Policy Model was partially a product of the dialogue 
established between the State and Civil Society. Although in different terms and between 
different actors, this dialogue continues until today.
6See, for example, https://
www.researchgate.net/
publication/257408083_Effects_
of_civil_society_involvement_
on_popular_legitimacy_
of_global_environmental_
governance
7Op. cit., p.2
8 Op. cit., p.3 
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structures), a lack of cooperation between CSOs, or a lack of awareness 
of the positive effects of CSI among policymakers. However, where these 
deficits exist, they represent an opportunity to leverage advantage, 
building stronger communities in the process. For example, ensuring 
CSI engagement in the policy process can lead to empowerment and 
increased participation among those who use drug care services. Through 
civil society, participation becomes easier because of the diversity and 
entrepreneurialism of CSOs. Participating requires optimism, energy and 
specialist skills that an individual may not often possess, but that a group 
of citizens can jointly develop. Being a patient or service user can often be 
disempowering, and those who organise to share information can reduce 
these burdens and empower themselves. This may result in an increased 
ability to manage their health care or an improvement in the quality and 
access of their care9. By empowering its citizens, a strong civil society is a 
component of a strong democracy.
Conclusion
As can be seen, the benefits of strong CSI for states are plentiful. Properly 
leveraged, CSI can help policymakers consider old problems in new ways, 
bringing a wealth of diverse experiences to bear on the issues facing 
modern societies. It can also improve things for citizens engaged in drug 
care systems, empowering them and encouraging participation. Finally, it 
can improve legitimacy, quality, understanding and applicability of policy 
initiatives, contributing to national and international strategic policy goals.
9Ibid.
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Assessments of civil society involvement are the first step for CSOs prior to 
planning specific activities. They are an important and helpful tool as they 
enable CSOs to:
 • identify the shortcomings and needs of their own organizations or, 
 more generally, those of civil society active in the field of drug 
 policy; this is a prerequisite for improving CSO capacities and the 
 overall conditions for CSI;
 • plan actions based on evidence, thereby making them more 
 effective;
 • show the results of their work, and therefore demonstrate 
 accountability towards existing and future donors; this is particularly 
 the case if the baseline assessment is part of a broader evaluation 
 or monitoring of effects (see chapter on monitoring and evaluation);
 • make the policy process more transparent by showing how   
 decisions are made, which CSO could make themselves heard, and 
 which arguments have not been considered; 
 • identify possible allies and to intensify cooperation with other CSOs. 
The choice of methods for conducting an assessment depends on the 
objectives of your action. Key questions to consider are: What do you want 
to achieve; which questions do you want to answer; and whom do you 
want to address. Do you want to demonstrate accountability towards 
(possible) donors or develop your internal capacities as a CSO? In these 
cases, the assessment would focus on your individual CSO and its external 
conditions, and the assessment could be either conducted by your own 
CSO (“self-assessment”) or by a third party, such as research institutions, 
donors or other CSOs (“external assessment”). If however, you want to 
raise awareness among the general public regarding the challenges 
of civil society involvement in harm reduction policies or advocate the 
implementation of regular civil society involvement mechanisms in drug 
prevention policies among policymakers, then your assessment should focus 
on the whole range of civil society actors active in these particular fields as 
well as their environment10. This chapter will focus on the implementation 
Assessing civil society involvement in drug policy 
Harald Lahusen
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of the latter and give practical examples for the assessment of the status 
of CSI on a national level11. 
The next step is to decide whether you will use quantitative or qualitative 
data as a basis for the assessment. Quantitative data are useful for showing 
differences, e.g. between different countries or between baseline and the 
termination of an intervention. Media representatives and policy-makers 
often prefer concise quantitative results to qualitative descriptions and 
interpretations. However, for assessments that explore new phenomena 
or complex relationships, qualitative analyses are often the method of 
choice. Depending on the purpose of the assessment, a combination of 
quantitative and qualitative elements may be helpful12.
If, for example, you want to assess the status of civil society involvement 
on the national level in different European Union member states and to 
make a comparison between them, it is useful to collect quantitative 
data. The following methods presented in this chapter focus on this kind of 
quantitative data collection.
1.1 Desk research
Desk research or secondary research is less cost and time intensive than 
field research because it does not include the phase of data collection, 
but instead analyses already existing data. By means of desk research, 
you can find a first indication of the situation of the civil society sector 
on the local, national or European level. It can also help you find existing 
knowledge gaps. Desk research can be conducted based on:
 • Scientific literature13; 
 • Grey literature – these are publications which have not been put 
   out by traditional commercial or academic publishers; including 
    e.g. reports, guidelines, recommendations and standards, 
 published by government agencies, international agencies, 
 universities, research organisations and NGOs;
 • Legal and policy documents (e.g. document analysis);
 • Media publications (e.g. content analysis); 
 10 UNDP (2010). A user’s guide 
to civil society assessments. 
11Overviews of 
different civil society 
assessment tools can be 
found in the following links: 
a) http://www.undp.
org/content/dam/undp/
documents/partners/civil_
society/publications/2010_
UNDP_A-Users-Guide-to-Civil-
Society-Assessments_EN.pdf 
(also available in 
French and Russian); 
b)http://www.icnl.org/
research/trends/trends5-1.pdf
12 UNDP (2010). A user’s guide 
to civil society assessments.
13A guide for conducting 
scientific literature reviews 
can be found here: https://
libguides.uwf.edu/litreview,
12
csidp
 • Data collected in the course of other research or projects which is 
   available for secondary analysis.
If, for example, you want to receive initial information about the status of 
civil society involvement on the national level in different European Union 
member states, your desk research could be based on the country drug 
reports which are available on the EMCDDA website for all EU member 
states. Another source could be the most recent National Drug Strategies 
and National Drug Action Plans of the member states.
1.2 Stakeholder interviews 
While desk research can provide you with preliminary information regarding 
the level of civil society involvement, often more information is needed to 
obtain a clearer picture of the situation. This further information can be 
collected by going into the field and collecting data e.g. via online based, 
quantitative interviews with relevant stakeholders. 
Identifying the stakeholders
Who the relevant stakeholders are, depends on the initial objective of 
your assessment. Once the objective has been formulated, the initial desk 
research can help identify the relevant stakeholders which need to be 
interviewed. Often it makes sense to include different perspectives on 
civil society involvement. If we refer again to our example of assessing 
civil society involvement on the national level in EU member states, import 
stakeholders are, for instance, the national agencies responsible for 
coordinating national drug policy, the national REITOX focal points which 
monitor the drug situation, and well-connected civil society organizations 
which are active on the level of national drug policy.
Drafting the questionnaire
Once the stakeholders have been identified, the questionnaire for the 
stakeholder interviews can be developed. During the development 
process one has to decide which dimensions of civil society involvement 
13
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the interviews shall focus on and how they should be measured. If available, 
it is helpful to use adequate existing instruments, because this will provide 
comparability of the data. An assessment of CSI on the national level of EU 
member states could include the following dimensions and measurements:
 • the number and types of CSO existing in the country and the level 
  of their involvement in both the development and implementation 
 of drug policy. An existing study published by the EMCDDA14 has 
 already distinguished between five types of CSOs: 
 o Alliance, coalition or network, civil society association; 
 o NGO or third sector organisation; 
 o professional or representative body;
 o user group. 
 • a rating of the level of CSI in the development and implementation 
    of drug policy in the following drug policy fields:
 o prevention,
 o treatment,
 o harm reduction, 
 o law enforcement, and
 o legal framework.
 • the mechanisms of CSI used in the development and 
 implementation of drug policy, herethe Council of Europe15  
 distinguishes between:
 o information
 o consultation
 o dialogue, and
 o partnership
 • a rating of the impact of CSI on the development and  
 implementation of drug policy.
14 EMCDDA (2013). Drug policy 
advocacy organisations in Europe. 
EMCDDA Papers. Publications 
Office of the European Union, 
Luxembourg. For more information 
see: http://www.emcdda. 
europa.eu/system/files/ 
publications/790/ 
TDAU13001ENN_457198.pdf
15Council of Europe (2009). 
Civil participation in the 
decision-making process. 
The code of good practice. 
CoE, Strasbourg. 
For more information see: https://rm.coe.int/CoERMPublicCommonSearchServices/
DisplayDCTMContent?documentId=09000016802eede1)
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Piloting the questionnaire
Before starting the full-scale survey, it is recommended to pilot the survey. 
This means that a small number of stakeholders will be invited to take part 
in the survey to find out whether all questions are understandable and 
appropriate for the target population. The pilot survey should be conducted 
under the same conditions as the full-scale survey (see ‘Conducting the 
survey’, below). However, after the participants have completed the survey, 
it can be useful to ask them about potential problems of understanding 
as well as further comments regarding the questionnaire. If needed, the 
questionnaire should be revised according to the needs of the participants, 
to prevent the collection of unreliable data. 
Conducting the survey
The questionnaire can be set up using an online survey tool. Some 
providers of online survey tools offer versions which can be used free of 
charge. Setting up an online survey is usually self-explanatory and does 
not require specific skills. Once the questionnaire has been set up within 
the survey tool, potential participants can be invited to take part in the 
survey via an email with a personalized link. This ensures that you can 
follow up on potential participants and send them reminders if they have 
not yet completed the questionnaire. If a survey participant follows the link 
sent via email, he or she is connected to an online entry form where the 
questionnaire can be completed. 
1.3 Analysing the data and disseminating the results
The responses are saved in a data base and can be exported to be 
analysed with spreadsheet calculation programmes or special statistical 
software. Here, freeware or shareware options are also available. The results 
of the analysis should be described in an assessment report. Besides the 
results, this report should also include an introduction into the topic and its 
relevance, a description of the methodology, a chapter with conclusions 
made based on the results, as well as an executive summary. The report 
can then be disseminated among the stakeholders and interested public 
via different channels of dissemination.
15
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2.1 Implementing involvement mechanisms 
Engaging CSOs in policy- and decision-making processes is a sound 
investment and a core element of good governance. It allows governments 
at national, regional and local level to tap wider sources of information, 
perspectives and potential solutions, and improves the quality of the 
decisions reached. It also contributes to strengthening the capacity of 
civil society itself16, 17.The focus now will be on the question of how CSOs 
can be involved to reach these goals. For creating evidence-based and 
effective drug policy at national, regional and local level, it is important 
that governments involve civil society organisations (CSOs) in policy- 
and decision-making processes in the most structured and sustainable 
way possible. This can be, for instance, through the mandatory inclusion 
of CSOs and their representatives in the inter-ministerial bodies and/or 
through multidisciplinary working groups in the field of drug policy. There 
are at least three levels of civil society involvement in drug policy. Figure 1 
below, adapted from OECD framework, show these levels: 
Figure 1: Defining Information, Consultation and Active Participation 
 
Organization for Economic Co-operation and Development (OECD) (2001). 
Citizens as Partners. Information, Consultation and Public Participation 
in Policy Making. PUMA Working Group on Strengthening Government-
Citizen Connections.
(Source: adapted from Health Canada, 2000)
Actions by policy- and decision-makers to enhance CSI
Matej Košir
16, 17 Torre, T., Braccini, A. M. 
and Spinelli R. (ed.) (2015). 
Empowering Organizations. 
Enabling Platforms and 
Artefacts. Springer.
Information Consultation Active Participation
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Information
Information is defined as a one-way relationship in which governments at 
national, regional or local level produce and deliver informative material 
for use by CSOs, such as annual reports in the field of drugs, brochures, 
leaflets etc. Access to information is a basic precondition for engaging 
CSOs. To strengthen the relationship with CSOs, governments must ensure 
that information is complete, objective, reliable, relevant, and easy to find 
and understand. One can talk both about “passive” access to information 
upon demand by CSOs and “active” measures by governments to 
disseminate information to CSOs, like access to public records such as 
statistical data, official gazettes, government websites, etc. There are 
several delivery mechanisms regarding “active” access to information, 
which may be either direct (e.g. information focal points, toll-free phone 
numbers) or indirect (e.g. media coverage, advertising etc.).
Consultation
Consultation is a two-way relationship in which CSOs provide feedback 
to governments. It is based on the prior definition by the government 
An example of implementing involvement mechanisms: The Regional Working Group on the 
Piemonte Harm Reduction Basic Levels of Care Protocol in Italy
In 2017, in the Piemonte Region, a Working Group promoted by the Health Department, 
including Civil Society (CS) and organizations of People Who Use Drugs (PWUD), wrote a 
Protocol on Harm Reduction Basic Levels of Care – the HR LEA – Livelli Essenziali di Assistenza-, 
which set the HR services to be delivered. HR LEA will allow PWUD to access harm reduction 
services in a free and guaranteed way all over the Region, overcoming current inequalities 
and making the right to health enforceable for PWUD. The role of CSOs (such as Third Sector 
professionals, NGOs active in research and advocacy fields and PWUD organizations) 
was crucial in contributing competencies and knowledge and in addressing political 
and human rights issues. In January 2018, the Group submitted the protocol to the Health 
Department for discussion and approval; the protocol will soon enter into force. Thanks 
to the positive evolution promoted by CSOs, the Group has become a stable organism, 
with the task to involve all the stakeholders in monitoring, evaluating and innovating harm 
reduction in Piemonte.
18
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of the issue on which CSOs’ views are being sought and requires the 
provision of information. Governments define the issues for consultations, 
set the questions and manage the process, while CSOs are invited and 
encouraged to contribute with their views and opinions. These can be 
related to  particular drug policy issues, such as surveys or opinion polls, draft 
strategies, or action plans and laws (e.g. comment and notice periods). 
Governments may also use tools for consultation with CSOs providing 
greater levels of interaction, such as in  public hearings, focus groups, 
panels, or workshops. Consultation has clear goals and rules defining the 
limits of its exercise and the government’s obligation to account for its use 
of CSOs’ input.
Active participation
Active participation is a relation based on partnership between CSOs and
government, in which CSOs actively engage in defining the process and 
content of policy- and decision-making. This can happen, for instance, 
through  forums, consensus conferences, inter-ministerial consultative 
bodies such as government commissions or working groups on drugs. 
Active participation acknowledges equal standing between government 
and  CSOs in setting the agenda, proposing policy options and shaping 
the policy dialogue. Yet, the responsibility for the final decision or policy 
formulation rests with government. Partnership as the highest level of active 
participation means that CSOs are empowered by actively participating 
An example of consultation: 
CS-Government Dialogue Session on the Italian position at UNGASS 2016
In 2015-2016 the network of Italian CSOs - Cartello di Genova - took actions on UNGASS 
process in order to make the Government position aligned with the European Union position, 
in favour of an “open and honest debate” on the Conventions outcomes. This was done 
in radical discontinuity with the role played by Berlusconi Government in 2009, when Italy 
broke the European front. The networking and advocacy action was successful, and the 
position held in UNGASS Assembly by the Italian Minister Orlando respected this goal. The 
limitation of this event was its being an occasional dialogue, and the challenge towards 
Vienna 2019, is to build a new and more structured opportunity, considering also a possible 
radical change of the scenario after the political elections in March 2018.
19
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in the drug policy- and decision-making processes in a structured and 
sustainable way. Participation provides sufficient time and flexibility to 
allow for the emergence of new ideas and proposals by CSOs, as well as 
mechanisms for their integration into government policy- and decision-
making processes. Active participations and efforts to engage CSOs in 
drug policy- and decision-making processes on a partnership basis are 
rare. This is especially the case when it comes to the holistic approach of 
involving CSOs from the whole spectrum of drug demand reduction, such 
as prevention, risk and harm reduction, treatment, social rehabilitation 
and reintegration, and recovery.
An example of active participation: CS involvement in national drug policy in Slovenia
In 2000, the Commission on Drugs of the Government of Slovenia was established by law 
(1999) and given the responsibility for drug policy at the inter-ministerial level. The Commission 
consists of representatives of nine ministries (health, internal affairs, labour, family and social 
affairs, education, interior, justice, finance, agriculture, defence and foreign affairs, and 
additionally of two representatives of CSOs). Due to very limited possibilities of CSOs in the 
field of prevention to be involved in the work of the Commission, its extension was proposed 
by a group/network of CSOs in the field of prevention. The network was formed by partners 
such as Prevention Platform, Red Cross Slovenia, Slovenian Coalition for Health, Environment 
and Tobacco Control, Network 25x25 and Youth Association No Excuse Slovenia. The action 
is still ongoing.
2.2 Funding
Civil Society Organisations 
Adequate financial, human and technical resources are needed if public 
information, consultation and active participation of CSOs in policy- and 
decision-making processes in the field of drug demand reduction are to 
be effective18. Governments have an incentive to provide funding to civil 
society for two reasons: (1) public policy outcomes are more legitimate if 
there is balanced input into the process; and (2), a vibrant civil society is 
important in its own right, as it can help build a common identity for a policy, 
solve problems and produce new ideas19. While government support of 
CSOs is seen as largely positive, it can have unintended consequences 
18Organization for Economic 
Co-operation and Develop-
ment (OECD) (2001). Citizens 
as Partners. Information, 
Consultation and Public 
Participation in Policy 
Making. PUMA Working 
Group on Strengthening 
Government-Citizen 
Connections.
19Mahoney, C. and 
Beckstrand, M. J. (2009). 
Following the Money: EU Fun-
ding of Civil Society 
Organizations. Paper 
prepared for presentation 
at the 11th bi-annual 
European Union Studies 
Association conference, 
Marina del Rey, LA, CA, US, 
23-25 April 2009. 
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as well. First, CSOs and especially more confrontational groups, may 
be co-opted by their government funders, toning down their critique 
of government institutions or altering their positions on issues20. Second, 
government support of CSOs can favour some segments of civil society 
over others (e.g treatment over prevention, prevention over risk and harm 
reduction), either purposefully driven by an agenda, or inadvertently.
There is a constant concern by many CSOs, civil society networks or 
umbrella organisations in Europe regarding non-sustainable funding of 
their services and programmes. Governments shall recognise the efforts 
of those CSOs, which put many human and financial resources in the 
implementation of evidence-based interventions (e.g. minimum quality 
standards in drug demand reduction) in their daily practice. That should 
be recognised by sustainable and long-term funding, inclusion of CSOs in 
policy- and decision-making processes, regular communication with CSOs 
on topics related to their daily work, and sufficient investment in education 
and training of staff in CSOs. Education and rtaining can be done, for 
instance, through the establishment of different educational and training 
programmes in the field of drug demand reduction. In many European 
countries, there is still no sufficient funding available for implementing 
evidence-based services and programmes by CSOs and this should be 
changed dramatically in the future21.
Research
Civil society organisations have a good position in society to collaborate 
in research work (on all levels) and to bring knowledge and expertise 
from research into policy- and decision-making processes. However, they 
often have trouble doing so, among other reasons, because of insufficient 
funding for such activities. Their participation increases the relevance of 
research for communities (giving the research a “human face”), but only 
if they are equal partners in the research process. Their inclusion can also 
be seen as motivation to actually apply the research results into practice . 
Evaluations (as a form of research) can inform CSOs whether their activities 
have any influence in practice or not, giving them necessary guidelines to 
achieve their goals. Because of their close connection to the communities, 
20McCarthy, J. D., Britt, D. and 
Wolfson, M. (1991). 
The Institutional Channeling 
of Social Movements by the 
State in the United States. 
Research in Social Movements, 
Conflicts and Change. 13:45-76.
21Civil Society Forum on Drugs (2014). Thematic Paper of the Civil Society Forum on 
Drugs on the EU minimum quality standards for drug demand reduction. Adopted in 
November 2014 at the annual meeting of CSFD.
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 22 Košir, M. (2010). 
Role of civil society 
organizations in research 
in the field of alcohol policy. 
Report for EU-funded project 
STEPS (FP7). Institute Utrip. 
Ljubljana.
CSOs can also evaluate the actual use of research results in the field. Due 
to their direct connection to practice, research initiated or executed by 
CSOs can be transferred into practice much more quickly and easily22. 
The inclusion of CSOs into research has also drawbacks which should not 
be neglected. Restrictions of CSOs inclusion into research are primarily the 
following (Delisle et al. 2005): 
 • Pre-conceived ideas of CSOs about research , such as the idea 
 that it is highly academic, elitist or theoretical, with no place for 
 CSOs, or the idea that research is done with the traditional top- 
 down approach ; 
 • Lack of training and financial  sources, as well as lack of time and 
 motivation (CSOs tend not to see themselves as a constituent in 
 the research process, and tend not to see research  as part of their 
 mandate; 
 • Breadth and type of research done by CSOs. CSOs generally do 
 smaller and qualitative studies, mostly not recognized by govern- 
 ments, research establishments, or agencies that prefer larger 
 quantitative studies; 
 • Weak connection of CSOs in research at international level. CSOs 
 are not sufficiently connected with various research project net 
 works, such as those funded by European Commission under Hori- 
 zon 2020 programme. 
Regarding future development, there are various needs for research and 
its funding) within CSOs. One example is to provide capacity building in the 
area of research, for instance, by organising various seminars, workshops, 
or symposiums on research to be attended by CSOs,. Another example is 
to further develop networks and partnerships bycreating and managing 
partner networks, as well as partnership with universities and other research 
establishments. This should all be recognized in its purpose to empower 
CSOs to be adequately involved in policy- and decision-making processes 
and to have a long term impact in the field of drug policy in Europe 
and beyond.
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An example of successful civil society involvement: 
The preparation of the process towards UNGASS 2016 in the Netherlands
In the years previous to UNGASS 2016, the international discussion around drugs was 
shifting from a punitive approach towards a harm reduction framework which advocated 
for human rights and the decriminalization of drug use. Given this turn, The Netherlands 
was considering how it could influence and bring its expertise into the discussion, as harm 
reduction strategies have been a central feature of its drug policy for decades. Despite the 
fact that the EU has no vote in the General Assembly  and that drug policy is a national 
competence of the state members, there was a desire from its Member States to ‘speak with 
one voice’ at the Special Session. Aware of the potential impact that UNGASS 2016 opens 
up, CSOs working in the harm reduction field in The Netherlands activated their partnerships 
with entities such a Harm Reduction International and International Drug Policy Consortium 
to engage in these international discussions. Considering the global scale of the event, 
the Dutch Ministry of Foreign Affairs and the Ministry of Health, Welfare and Sports set up 
an informal consultation network of international and national organizations with a global 
scope. At the 58th Session of the CND, the Netherlands incorporated CSOs in its delegation 
in Vienna. With this gesture, CSOs were granted not only the possibility to contribute to the 
position of the delegation during the Session and on its final statement, but also to engage 
into spaces, discussions and information which otherwise CSOs would not have access to.
2.3 Conclusion
Governments at all levels must invest adequate time and (financial) 
resources in building robust legal, policy and institutional frameworks, 
developing appropriate tools and evaluating their own performance in 
engaging CSOs in policy- and decision-making processes. Commitment 
and leadership by politicians and senior public officials are also key 
ingredients for CSI. 
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It takes two to tango 
Meaningful civil society involvement requires input and action from both 
sides: policy- and decision makers on the one hand and civil society 
organisations on the other hand. As policy makers might be more hesitant 
towards this process, CSOs should be ready and able to fulfil a proactive 
and leading role in this process. Different aspects are key when it comes to 
the development of meaningful civil society involvement. 
3.1 Local or national CSI 
CSI is organised on the local and national level and CSOs need to assess 
which level of involvement makes sense to them. CSI on the local level 
becomes more and more important, due to the decentralisation (shift of 
responsibilities from the national to the local governments) in most European 
countries. Local CSOs can be quite influential in the development and 
implementation of local drug policies. This might happen in consultation 
rounds or working groups which have clear responsibilities and a direct link 
to the solution for practical local problems. Thus, local CSI is more practice-
oriented and can have a direct impact on the living conditions of people 
who use drugs (PWUD). Local CSOs, however, are often not involved at all 
when it comes to the development of national drug policies. 
National CSI is less practice-based and specific. Consultations with 
CSOs might focus on national drug policies, strategies, action plans and 
guidelines. CSOs who are engaged in drug policy on national level are 
often national centres of expertise, sometimes with local branches 
or organisations. 
Actions by civil society organisations to enhance CSI
Katrin Schiffer
An example of a CSO active on the national level: 
The National Family Support Network (NFSN) in Ireland
The National Family Support Network (NFSN) is a CSO active across Ireland, working primarily 
with families affected by drug use. It is an autonomous self-help organisation that respects 
the lived experiences of families affected by drug use, in a welcoming non-judgemental 
25
csidp
Although CSI on the local and national level requires different knowledge 
and capacities, some success elements are similar. CSOs need to have 
the capacity and resources to communicate with policy makers and other 
stakeholders and should be able to formulate certain policy messages in a 
sensible way. The following factors can support this process23. 
3.2 Capacity building24
Most CSOs in the drug field are NGOs working directly with the target group 
(People Who Use Drugs) and providing harm reduction services, psycho-
social assistance, recovery programmes and/or medical services. Only a 
limited number of CSOs work in the field of policy and advocacy. 
As a member of a CSO in the drug field, you know your target group very 
well. You know the structural problems, the individual needs of PWUDs 
and the barriers which are encountered when services are provided to 
the target group. However, this practical knowledge and expertise does 
not automatically lead to practical know-how and the ability to inform 
and influence drug policy. CSI and advocacy requires organisational 
capacities as well as capacities and skills on an individual level. 
atmosphere. The National Family Support Network primarily supports the development 
of family support groups and networks throughout the island of Ireland; it also represents 
and advocates for the needs of families at a national policy level. To better address the 
issue of drug-related intimidation, NSFN worked with An Garda Siochána (the Irish police 
force) to create a tailored solution in the Drug Related Intimidation Reporting Programme, 
aiming at responding to the needs of people who use drugs and family members who are 
experiencing drug related intimidation.
 23 CIVICUS/Civil Society Europe (2016). Civic Space in Europe Survey. 
http://www.civicus.org/images/CivicSpaceinEuropeSurveyReport_FINAL251015.pdf
24  Raynor, J. et al (2009). What makes an effective advocacy organization. 
A framework for determining advocacy capacity. TCC group. 
http://www.tccgrp.com/pdfs/EffectiveAdvocacy_final.pdf
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Capacities on organisational level
Most advocacy tools for CSOs aim to provide staff members with technical 
capacities and skills. There is less information and guidance on what kind 
of capacities are needed on the organisational level. 
Capacities on the organisational level include25:
 • Leadership capacity 
 • Strategic capacity
 • Management capacity 
 • Technical capacity 
Leadership capacity 
The most important prerequisite for the development and implementation 
25 Connolly, P.et al. (2003). 
Building the Capacity of 
Capacity Builders. A study of 
Management Support and 
Field-Building Organizations in 
the Nonprofit Sector.
An example of the importance of CSO capacities: 
The organisation of shelter and social support for people experiencing homelessness and 
substance use disorder in Amsterdam, Netherlands
Since 1st of January 2015, the municipal administrations in the Netherlands have become 
responsible for the organization of the social support for its citizens, and for the quality and 
continuity of the services. As a result of this decentralization process, an integrated service 
for social support in which public health, prevention, care, welfare, housing, and work has 
been the main goal to be attained. The municipality of Amsterdam and a wide range of 
stakeholders, service providers and CSOs have been examining together the strategies 
through which to implement this change of policy, and how to improve the existing structures 
and care programs. The specific goal of the Housing Program for Vulnerable Groups is to 
offer, within three months, a suitable accommodation to those Amsterdam citizens who find 
themselves in an urgent housing need, including marginalized PWUD. Collaboration with 
all stakeholders (municipality departments, public health services, housing corporations, 
care providers, police, CSOs and regional institutions) is central. CSOs produce a body of 
knowledge based on practical experience upon which successful and efficient services 
can be created. CSOs are instrumental in feeding these insights into the administrative 
agencies, allowing the work processes and policies to align themselves with the reality of 
the services needed.
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of meaningful CSI is the overall political commitment of the organisation. 
In this regard, the organisation needs the capacity to:
 • formulate and propagate an authentic political vision and mission, 
 based on the knowledge, expertise and close relationship to com- 
 munity members;
 • cooperate with and relate to relevant stakeholders, including other 
 CSOs, community members and policy-makers; 
 • inspire and motivate relevant stakeholders;
 • develop a strong reputation as a reliable and knowledgeable 
 partner.
CSOs who have engaged successfully in advocacy activities on the local, 
national or European level have developed and formulated a policy 
strategy which is widely shared and communicated. They can rely on a large 
network of cooperative partners and allies and are regularly engaged in 
consultations with governmental institutions and representatives. 
An example of CSO leadership: 
Supporting the implementation of supervised injecting facilities in Ireland
To support the implementation of supervised injecting facilities (SIF) in Ireland, Ana 
Liffey worked with non-CSO actors to help identify and address the key legal barriers 
to SIF implementation. The organisation sought the support of the Voluntary Assistance 
Scheme (VAS) of the Bar of Ireland. The VAS agreed and put together a legislative drafting 
committee - a group of barristers who generously gave their time pro bono to work with 
the organisation; the output, in early 2015, was a legal opinion from the committee along 
with draft legislation which, if introduced, would establish a legal framework within which 
SIF could operate in Ireland. Ana Liffey could provide a detailed analysis which could assist 
politicians and civil servants in their work on the topic. The result of this process was that the 
Oireachtas (Irish Parliament) passed the Misuse of Drugs (Supervised Injecting Facilities) Act 
2017, which was signed into law by the President of Ireland in May 2017. Ireland has now a 
legal framework under which SIFs can legally operate.
28
csidp
Strategic capacity
In addition to the leadership capacity, CSOs should be able to think and 
act strategically. This includes the strategic positioning of the organisation 
and the ability to develop a strategic advocacy approach. 
CSOs should be aware of their current position and role in the field by 
considering the following questions: 
 • Are they initiators and leaders of a process or do they follow the 
 initiatives of others? 
 • Are they satisfied with their role or do they aspire after a  
 different role? 
 • What is needed to fulfil such a role (capacities, skills, resources)?
 • What is the reputation of the organisation among other  
 stakeholders? 
Many CSOs do not reflect upon their role in relation to other stakeholders. 
This might lead to confusion and misunderstandings. Others might expect 
more leadership or support, or might feel threatened by certain actions. 
Strategic positioning is important and requires active, transparent and 
open interaction with other stakeholders. If an organisation aspires to 
another role, it is important to know potential supporters and opponents 
and to assess whether they have the capacities, skills and resources to fulfil 
this role. 
Knowing the role of the organisation in the field helps to move things 
forward. Subsequently, it is necessary to plan and organise the CSI 
process accordingly. This includes the assessment of needs and problems, 
the formulation of short- and long-term objectives, the development 
of strategic partnerships and the development, implementation and 
evaluation of a SMART26 and feasible action plan. 
26 SMART = methodology to 
measure if and to what extent 
aims and objectives have 
been reached. 
S = Specific, M = Measurable, 
A = Appropriate, R = Realistic, 
T = Timebound
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Management capacity
Once CSOs have decided to develop and implement a strategic 
approach, it is essential to safeguard that this process is managed and 
organised in a proper way. This includes:
 • the communication within the organisation: establishing short lines 
 of communication; enabling involved staff members to represent 
 the organisation and take decisions on its behalf
 • the communication with other stakeholders to ensure smooth, 
 reliable and direct interaction 
 • the dedication of sufficient resources to ensure that the organisation 
 can participate in the CSI process
Technical capacity 
The technical capacity of an organisation is an important prerequisite for 
effective CSI. CSOs need to have the knowledge, capacities and skills to 
perform their tasks. This includes, for example: 
A result of strategic planning: 
The inclusion of Harm Reduction as a prevention pillar in the new National AIDS Plan in Italy
In November 2017, the State/Region Conference ratified the adoption of the new National 
HIV/AIDS Plan, submitted by the Italian Ministry of Health in December 2016. The new Plan was 
issued after twenty years had passed from the preceding one. It is an innovative document 
based on the most recent scientific evidence; Italian civil society (both community based 
organizations and patients’ organizations) largely contributed to its preparation. Those civil 
society organizations with relevant competence and operational experience in the field 
of HIV and drugs that are part of the Technical Health Committee at the Ministry of Health 
have specifically contributed to the general structure of the Plan and supervised the 
sections dedicated to people using drugs, prisoners and sex workers. After many years of 
ostracism, Harm Reduction strategies, policies and interventions have been finally included 
in the Plan as one of the pillars of combined prevention. This achievement was surely a big 
win for Italian CS.
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 • knowledge of the legal situation on national and/or local level;
 • knowledge and information on problems, barriers and needs;
 • knowledge of potential windows of opportunity for advocacy; 
 • providing technical and other support to staff members, such as 
 training and capacity building. 
Capacities on individual (staff) level
Organisational capacities are essential for organisations who want 
to engage in CSI. However, everything depends on the capacities of 
individual staff members. They need to understand how advocacy works 
and must know the tricks of the trade. They need to be political, strategic 
and diplomatic, must communicate in a clever, sensitive and sensible 
way, and should be able to cooperate, connect and build coalitions and 
strategic partnerships. 
Most CSOs do not have the resources for employing an advocacy officer.
Instead, staff members combine practical work with advocacy activities. 
This is feasible and realistic and also brings advantages, because practical 
How CSO knowledge and experience foster CSI: 
APDES and the National Forum of Civil Society (FNSC) in Portugal
In 2010, APDES joined the National Forum of Civil Society (FNSC), which is an advisory 
structure of the National Coordination for HIV/AIDS, and since 2017 also for Tuberculosis 
and Hepatitis. Based on the work that the entities do, the FNSC is recognized as a dialogue 
forum capable of giving a voice to people  affected by and those  living with HIV / AIDS, 
promoting the critical participation of those involved in all aspects of the response to the 
epidemic. The FNSC is also a privileged space for advocacy for certain topics such as: 
early diagnosis and the possibility of using HIV rapid tests in a community setting; opening 
new funding for HIV / AIDS prevention in Portugal; Harm Reduction funding and Needle 
Exchange Program (PTS); and the change of public health policies. Being a representative 
of FNSC gave APDES the opportunity to play a significant role in the dialogue with policy 
makers thanks to their knowledge, experience and competencies. One example was the 
collaboration with the Monitoring Commission of the Needle Exchange Program and its 
consequent contribution to the development of the HR strategy and related interventions.
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experience and insights from the field can support and feed the advocacy 
activities in an authentic way. 
Knowing that most staff members within CSOs do not have a formal training 
or education in the field of policy, advocacy and/or communication, it is 
important that they can receive training in different areas, including:  
 • Policy and political frameworks: understand how the policy 
 system works and how policies are developed, which ministries, 
 departments and individuals are involved in decision making, which 
 consultation and or information mechanisms exist with CSOs and how 
 CSI is organised;
 • Drug policies and legislation: know the policies and the legislation 
 on local and national level to understand how they influence the 
 situation of PWUDs;
 • Policy cycles: know the relevant policy cycles on local and 
 national level and understand when advocacy activities need to 
 be organised to create impact, as well as to be aware of potential 
 windows of opportunity; 
 • Strategic partnerships: be aware of the relevant stakeholders in 
 the field and know their role and position; know which stakeholders 
 might support (allies) or oppose (enemies); motivate, inspire and 
 stimulate potential allies to support specific advocacy activities;
 • Communication: capacity to communicate in a sensitive, sensible 
 and diplomatic way with different kind of stakeholders, including 
 policy makers, other CSOs and community members;
 • Advocacy strategy and action plan: understand how to develop, 
 implement and evaluate an advocacy strategy and action plan; 
 to have strategic thinking and acting, without losing the authentic 
 SC perspective. 
3.3 Acquiring funds
The level of CSI depends on different criteria, such as the willingness of 
policy- and decision makers to consult CSOs as well as the capacities of 
CSOs and their staff members. Just as important in this context is having 
access to financial resources for service provision, CSI and advocacy. 
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Challenges for funding 
No specific funding for CSI and advocacy
Most CSOs in the drug field are service providers, rather than advocacy 
organisations. Their main focus is to help and support PWUD in different 
ways, for instance, with harm reduction services, drug prevention, 
treatment or recovery programmes. Funding for these activities is in most 
cases acquired by national, regional or local governmental funding 
systems. CSOs are expected to provide policy makers with information 
from the field, if needed. But most policy makers are hesitant to provide 
funding for more active involvement, unsolicited interference and critical 
remarks. Specific funding for advocacy and CSI is mostly not provided. 
CSI is seen as a voluntary activity which is carried out on top of the 
daily business. 
Less funding for CSOs 
The economic crisis which started in 2008 and still influences European 
economies has resulted in austerity measures and severe budget cuts 
which strongly affected all kinds of interventions targeting marginalised 
groups such as PWUD. 
In some countries, CSOs can obtain financial support from international 
funders, including the Global Fund, the European Union or private 
foundations such as the Open Society Foundation. Funding is available 
for specific activities only and is limited for a certain period of time. The 
Open Society Foundation specifically supports activities which strengthen 
(advocacy) actions of CSOs, having mind that democratic societies need 
a vibrant civil society sector. Due to the current political developments 
in some Eastern European countries, such as Poland and Hungary, these 
funding mechanisms are under pressure as well. 
International funding can support the development of certain CS initiatives, 
but is normally not intended to provide ongoing structural financial 
support. The Global Fund and the Open Society Foundation have already 
withdrawn from a number of countries in Europe. While hope remained 
that national governments would take over the funding responsibility, this 
has not happened in most of the cases. Instead, many CSOs, especially 
harm reduction services, were closed down or suffered major budget cuts. 
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In addition, there are problems concerning policy developments in some 
Central European countries such as Hungary and Poland. These countries 
introduced new policies which hinder NGOs in providing services to 
marginalised groups and in engaging in CSI. Funding from international 
donors is becoming more problematic, as CSOs which receive funding 
from these donors are classified as international agents. This is a worrying 
development which makes even more important  the support from other 
countries, from the European Commission and the civil society sector 
in general27. 
Creating opportunities for funding28, 29 
Funding is essential for CSOs to provide their services and to engage in 
CSI. CSOs have developed their own styles and ways of communication 
with the relevant policy and decision makers. This interaction is strongly 
influenced by the specific cultural and political situation and by the 
relationship between policy makers, decision makers and civil society. 
Nevertheless, there are some basic principles which can help CSOs to 
gain support: 
Building a dialogue with policy makers
 • Know the relevant people and their responsibilities. Some individuals 
 can influence certain policies, while others are influential when it 
 comes to the distribution of funding. These responsibilities might 
 seem obvious, but sometimes these relationships are based on 
 personal likes or dislikes. This means that one officer might have 
 more influence than another; 
 • Build trustful relationships. Build trustful relations with all relevant 
 stakeholders, including policy and decision makers. Stick to your 
 main contact person and inform him or her when you approach 
 someone from a different or higher position. Transparent 
 communication can help in creating a good reputation as a 
 reliable partner;  
 • Provide information and input. Inform policy and decision makers 
 on a regular basis about the developments in the field. Provide 
 them with information which is relevant to them, but don’t forget to 
 include what is important for you; 
27CIVICUS/Civil Society 
Europe (2016). Civic Space 
in Europe Survey. 
http://www.civicus.org/images/
CivicSpaceinEuropeSurveyReport_ 
FINAL251015.pdf
28 http://www.advocacyfunding.
co.uk/advocacy-grants-fundable/ 
29http://www.advocacyfunding.
co.uk/value-for-money/
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 • Be supportive and diplomatic. Offer support if needed. This can 
 include the provision of information and data if policy makers ask 
 for it, but can also include the organisation of field visits for policy 
 makers. Being supportive and diplomatic does not mean that you 
 cannot be critical, but constructive feedback is more effective 
 than emotional criticism and praise. 
Showing the benefits of CSOs and CSI
 • Inside knowledge. Know what happens in the field. You are in 
 daily contact with PWUD and can easily identify new developments, 
 including new drug trends and drug using patterns. Make this 
 clear to policy and decision makers by regularly providing them 
 with (short and clear) information  and keep in mind that also 
 positive developments should be reported and documented; 
 • Feasible and practical solutions. You can provide practical solutions 
 for new and old problems. This applies in particular to low-threshold 
 interventions which can directly impact and improve the situation 
 of PWUD. If new interventions are implemented, make sure that 
 these are monitored and evaluated to show the direct effects. This 
 can support future advocacy activities; 
 • Evidence and practice based approach. If possible, use existing 
 evidence and showcase good practice examples as well. Well 
 formulated arguments can be convincing;
 • Cost-effective. Most interventions are not only feasible and 
 evidence-based, but also cost-effective.  Make this point clear and 
 be as specific as possible. How cost-effective are you and to which 
 extent? Use practical examples; 
 • Cooperation versus opposition. Strengthen the cooperation with 
 other CSOs in the field and describe and present the ways in which 
 you cooperate. Cooperation works better than opposition 
 and concurrence.
35
csidp
Monitor, report and share information
 • Provide short and clear documentation. Provide policy and decision 
 makers with progress reports on a regular basis and highlight what 
 you have achieved. Use factsheets rather than extensive reports.
 • Know what is relevant. Provide policy makers with information 
 which is relevant to them. Don’t overload them with information. Be 
 short, comprehensive and precise. 
 • Highlight successes. Documentation and reporting should describe 
 the state of affairs, relevant developments, potential problems, but 
 also positive feedbacks. 
 • Showcase individual stories. Sharing data and information is 
 important to provide an overview of the overall situation. However, 
 policy makers do not know the daily reality of PWUD and other 
 marginalised groups. Include personal stories in your reporting 
 and make it personal by describing in which ways policies and 
 interventions can influence the life of people who use drugs, in a 
 positive or a negative way. 
An example of CSO cooperation and struggle for funding: 
The organisation of harm reduction services in Portugal
Some care services -mostly harm reduction responses but also some prevention, treatment 
and reinsertion interventions- are provided in local settings by NGOs based on an 
agreement between these NGOs and the State (represented by SICAD, the official body 
responsible for drug policies). The State regulates, funds and monitors the services which 
are designed and implemented by the NGOs. This means that interventions are a product 
of cooperative relations between the State and civil society. The National Harm Reduction 
Network, which includes most of the existing projects, has a long history of cooperation 
with SICAD. However, some problems are yet to be negotiated, such as the 100% funding 
of services (instead of the current 80%) and a more formal and structured National Forum 
for Civil Society organizations.
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30http://www.fabriders.net/
pyramid1/
31http://www.fabriders.net/
spectrogram-stakeholder-
map/
3.4 Building coalitions30, 31
CSOs in the drug field are not acting as lone wolves. Other organisations 
and institutions provide services to PWUD as well. These can include social 
and health service providers, harm reduction, prevention and treatment 
services, as well as recovery programmes.
Obstacles for building coalitions
Cooperation between these services is strongly recommended, assuming 
that services can complement each other and that the whole is more than 
the sum of its parts. However, this is not always the case. Some organisations 
may not wish to cooperate with each other because of:
 • Ideological differences. This applies in particular to countries 
 where the drug policy discussion is strongly influenced by ideology 
 rather than evidence and pragmatism. Policy makers and other 
 service providers might not support harm reduction approaches, 
 for instance; 
 • Methodological differences. Additionally, service providers might 
 have different ideas about the methodology of work. Although 
 these differences seem to be less polarising than ideology, they can 
 create serious obstacles. Methodological differences can also be 
 based on principles, such as providing anonymous and confidential 
 services which seriously affect the relationship between 
 organisation and service provider; 
An example of a coalition: CityWide and Decriminalisation in Ireland
CityWide is a national network of community activists and community organisations that 
are involved in responding to Ireland’s drugs crisis. Originally focused on Dublin, CityWide 
now works nationally to promote and support a community development approach to the 
drugs problem. This means involving the people who are most affected by the problem in 
dealing with it: people who use drugs, their families and communities. As an organisation, 
CityWide represents the community sector on national policy structures being an influential 
CSO voice in Irish drug policy. To support the national discussion around decriminalisation 
of possession of drugs for personal use, CityWide took a leading role among community 
groups.
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 • Problematic relations between Governmental Organizations (GOs) 
 and NGOs. Countries which have a stable CS sector cooperate 
 regularly with (semi)-governmental organisations. This becomes 
 more difficult in countries where CS still has to assert itself or where 
 political development infringes on the rights of CSOs. GOs will then 
 represent the governmental power, and service provision might be 
 characterized by a type of citizen control. In such a situation, NGOs 
 will not easily cooperate – as this can affect their reputation among 
 the target group; 
 • Funding competition. Even if the landscape of service providers, 
 consisting of NGOs and GOs looks healthy and divers, cooperation is 
 not always obvious. CSOs are most often competitors, as they 
 depend on the same funding mechanisms. Some municipalities 
 have chosen to work with procurement systems which increase 
 the competition between CSOs, and gives the idea that social and 
 drug services can be organised similarly to market-driven sectors. 
 Competition may have a positive influence on the quality and cost- 
 effectiveness of services, however it may also undermine the 
 provision of good and effective services and estrange service 
 providers from each other. 
Strategies for cooperation
It is obvious that cooperation between CSOs is beneficial. Not only in regard 
to service provision, by complementing each other’s services, but also 
in regard to CSI and advocacy. Cooperation makes each organisation 
stronger, and although there might be obvious reasons not cooperate, 
CSOs should carefully assess whether coalitions can be built at some point. 
Some strategies for cooperation are:
 • Stakeholders mapping and power analysis. Assess all relevant 
 stakeholders, including other CSOs, policy- and decision makers 
 and indicate what kinds of influence they have and whether 
 they support or oppose your case. Additionally, try to describe the 
 interaction between different players. Who can influence whom, 
 who likes or dislikes certain people? The more information you 
 have, the better;
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 • Focus on your allies. Once you have identified your allies, enemies 
 and the in-betweens (the neutral parties), focus on your allies first. 
 Motivate them to support your case. Do not invest energy and time 
 in convincing those who cannot be convinced; 
 • Convince the in-betweens. The neutral parties need to receive 
 relevant information which will convince them to support your 
 case. Engage them in the process, even if they are not yet 
 convinced. Active participation might turn them into an active ally; 
 • Prepare a common strategy: Preparing a common strategy will 
 help you to create more commitment and involvement. Divide and 
 share responsibilities and present yourself to the outside world as 
 a consortium;  
 • Celebrate successes and learn in case of failure. Analyse and 
 evaluate your actions. Celebrate your successes, even if you could 
 not achieve everything you wanted. If you did not succeed, don’t 
 blame each other. Try to identify what went wrong. Failure is often 
 the first step to success; 
 • Maintain cooperation. Continue and maintain your cooperation 
 by organising regular meetings, even if there is no common action 
 needed at that time. You will need each other again at some point. 
 Regular exchange of information makes it easier to react quickly 
 if needed.  
An example of  strategic cooperation: 
Setting up a working group to discuss a platform for change in drug policy in Bulgaria
In 2012, a group of CSOs developed a Platform for change with motivated suggestions 
for grounding reforms in the philosophy of the Bulgarian drug policy. The document was 
submitted to the National Drug Council and a working group was established by the 
Minister of Health to analysed the proposed changes: revision of the drug possession 
penalties and of the cannabis policy, introduction of alternative penalties for drug addicted 
offenders, strengthening of the civil society’s participation in the decision-making process, 
improvement of funding schemes and introduction of effective evaluation mechanisms. The 
working group didn’t reach a consensus for most of the propositions but nevertheless it was 
the first example of a formally established dialogue forum between the policy makers and 
CSOs and a useful dialogue experience for both sides. 
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3.5 Public awareness-raising32:
Public opinion is an influential factor for politicians and decision makers, as 
their re-election might depend on it. If well-planned and organised, it can 
support the lobby and advocacy work of CSOs. 
Planning and organising public awareness campaigns
Public awareness-raising includes more than only selling a good idea 
and providing information to the public. The overall purpose of the 
awareness-raising process is to change attitudes, behaviours and beliefs 
with the intention to influence them positively in the achievement of a pre-
defined goal. This is a challenging process, especially if it concerns the 
situation of marginalised groups, such as drug users. The public opinion 
is rather negative towards these groups, and based on prejudices and 
assumptions. If you decide to organise a public-awareness campaign you 
need to understand the principles of communication. The effectiveness 
of a campaign stands and falls with decent planning and clearly defined 
goals. No planning can cause more bad than good. 
A well-planned campaign includes four key components: 
Message
 • What is your central message? – be clear and specific 
 • What do you want to achieve (goals and objectives)? – make sure 
 that the central message(s) captures the overall goal 
Audience
 • Who needs to be involved in your campaign? – this can include 
 public authorities, community members, other CSOs or a certain 
 group of citizens
 • Whom do you want to address (target audience)? – be as specific 
 as possible
 • What is the scope of the campaign? – number of people you want 
 to reach  32Sayers, R. (2006). Principles 
of awareness-raising. UNESCO. 
http://unesdoc.unesco.org/
images/0014/001476/147637e.
pdf
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Strategy
 • Which communication strategy should be used? – make sure that 
 you choose the most effective strategy for the target audience 
 • Which information needs to be included? – don’t overload your 
 audience with too much information
 • What is needed to convince your audience? – level of involvement 
 and influence of the audience 
Timing
 • What is the timeframe of the campaign? – include relevant 
 moments for advocacy, monitoring and evaluation 
3.6 Public awareness-raising strategies 
There are numerous ways to organise awareness-raising. The effectiveness 
of a campaign strongly depends on which strategy is chosen and whether 
this strategy fits the target audience. A mix of communication strategies 
will increase the effectiveness of your campaign. 
Common approaches and strategies are: 
 • Personal communication, such as community and stakeholder 
 meetings, public forums, presentations, workshops, social events 
 and cultural events;
 • Mass communication, such as printed materials, audio-visual 
 resources, websites, social media, and media interviews 
 (newspaper, radio and TV);
 • Education and training, such as formal and informal education, 
 train-the trainer programs, and exhibitions;
 • Public Relations activities, such as regular media briefings, 
 involvement of celebrities, and organisation of benefit events;
 • Advocacy activities, such as building coalitions, organising meetings 
 with policy makers, and launching policy recommendations. 
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3.7 Media advocacy actions33 
Media advocacy is a specific strategy for raising awareness and changing 
the beliefs, attitudes and behaviours of your target audience. Media 
advocacy is the use of any form of media which helps you to promote 
your advocacy message. This can include newspapers, radio, television 
and internet. 
Challenges and opportunities 
Media advocacy requires specific capabilities. You need to cooperate 
with the media and you need to know which information must be shared. 
Some information will support your case, other information might do the 
opposite. Media advocacy is risky. You can’t control the media and you 
never know how your advocacy message will be shared and interpreted. 
There are many examples where media attention caused more bad than 
good. This is particularly likely when it comes to marginalised groups, such as 
people who use drugs. CSOs want to inform the public, reduce prejudices 
and create more understanding. Journalists want to inform as well, and 
while most want to be objective, they also have their own biases. They do 
not always have the time to conduct extensive background research and 
their message will depend on the information that is most easily available. 
They might speak to people who have different opinions – your opponents 
– and they might prefer their opinion. All these factors make it challenging 
to use the media for your own cause. 
Nevertheless, when you know the pitfalls and act cautiously, media can 
bring many advantages. You will be able to reach a diverse and large 
audience. You can share your message, raise awareness, be thought-
provoking and tell a different story which has probably never been told 
before34. 
Using the media 
Media advocacy can be used to: 
 • Inform or educate the public on certain topics and developments; 
33https://ctb.ku.edu/en/
table-of-contents/advocacy/
media-advocacy
 34 https://ctb.ku.edu/en/
table-of-contents/advocacy/
media-advocacy/working-
with-media/main
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35https://ctb.ku.edu/en/
table-of-contents/advocacy/
media-advocacy/befriend-
media/main
 • Recast problems by creating an understanding and reframing 
 problems as everyone’s problem. This can be done, for instance, 
 by showing that drug use happens everywhere; 
 • Pressure policy makers to act or change policies;
 • Promote your work or a certain activity and share your message;
 • Mobilise professionals and community members to become 
 engaged; 
 • Give a voice to community members and let them tell their story.
If you want to use the media, you have to choose a good moment. Not 
everything which is important to you is relevant to the media. Timing is, 
therefore, essential. Use certain moments and events which are interesting 
to the media such as conferences, the start of a new project, the launch 
of a report, the adoption of a new law. You can also tie your message 
to something which has recently happened and caused a lot of media 
attention. Be prepared when the media contacts you. You should know 
what to say and have information available which can be shared easily. 
Working with the media requires certain capacities and skills. These tips 
might help you use the media in the most effective way: 
Establish personal relationships35
It will definitely help you to create a trustful relationship with different 
An example of media advocacy actions: Advocacy for medical cannabis in Bulgaria
In Bulgaria medical cannabis is not legal. There is a growing number of medical users and 
there are several court cases in which some of them are treated as criminals. Two CSOs are 
active on this issue and between 2012 and 2015 they tried to change the policies on the 
topic. They used personal stories in a successful strategy to attract media attention and to 
change public opinion. Based on that they implemented a series of activities to advocate 
for classification of cannabis/THC as a drug with medical application. Main targets were 
the Ministry of Health and the National Drug Council. Although CSOs were relatively 
successful in partaking the process and managed to have three reports showing sound 
scientific evidence supporting their claims, they didn’t manage to change the policies due 
to the conservative attitude of authorities and a number of procedural tricks used by them.
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journalists. The longer and better you know them, the more you can control 
how your message is being sold. 
Be cooperative36
Media advocacy is give-and-take. You want them to tell your story, but 
something needs to be in for them as well. This means you should: 
 • Be available when they need something from you. This can be a 
 statement or a reaction regarding an event which has caused 
 media attention. Be proactive, prepare yourself and use this 
 opportunity to share your message;
 • Be as open as possible. Let them know what you want and expect. 
 This will allow the media to understand your issue and you will be 
 able to negotiate what is possible and what is not;
 • Be trustworthy and accurate and do not state anything proven 
 to be wrong. This will not help your case and can damage your 
 reputation;
 • Be supportive and inform them about relevant developments and 
 events which might be important and interesting to them.
Think and act strategically 
Using and working with the media requires planning and strategic thinking 
and acting. This applies to all kinds of advocacy activities. Be aware of 
potential pitfalls and obstacles when you develop your strategy. Learn 
from previous experiences, successes and failures. 
3.8 Evaluation and Monitoring37
Evaluation and monitoring are important and powerful tools to support 
and improve the work of CSOs. Evaluation can show and prove the 
impact of a certain intervention. It can provide CSOs with arguments and 
relevant information to support their case. Advocacy activities can also 
be monitored and evaluated. It is clearly linked to the development of an 
advocacy strategy and can show whether a strategy was successful or not. 
 36https://ctb.ku.edu/en/
table-of-contents/advocacy/
media-advocacy/meet-
media/main
37Correlation Network: 
Effective Evaluation: An 
introduction for grassroot 
organisations; http://
correlation-net.org/images/
stories/pdfs/products_corr3/
evaluation_guide_web.pdf
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Although monitoring and evaluation tasks are often perceived as annoying 
and time-consuming, they help to:
 • specifically plan interventions and organise the workflow;
 • formulate aims and objectives; 
 • monitor whether the intervention is carried out according to the 
 work plan;
 • measure whether the intervention has achieved pre-defined aims 
 and objectives;
 • detect problems and bottlenecks at an early stage of the 
 implementation of the intervention; 
 • provide guidance on future interventions (evidence and/or 
 practice-based);
 • inform funding agencies and governments on the activities of a CSO 
Plans for monitoring and evaluation should be made at the very beginning 
of the intervention and should include a description of the aims, objectives, 
activities and indicators. They also should be linked to a timeframe, to all 
available resources and should address potential barriers and bottlenecks 
during the implementation. 
An example of how CSO monitoring and expertise can inform drug policy: Mainline & The 
Ministry of Health Welfare & Sports (VWS) in the Netherlands
This action describes the exchange of information between a Civil Society Organisation 
and the Dutch Ministry of Health. Mainline is a harm reduction organization that operates on 
a national and international level. Its mission is to promote health and fulfil the human rights 
of PWUD with respect for the individual drug user’s freedom of choices and capabilities. 
For decades harm reduction has been a central feature in Dutch drug policy, which 
aims at lowering drug-induced deaths and drug-related infectious diseases, preventing 
drug-related emergencies as well as reducing public nuisance. In the Netherlands, harm 
reduction activities are implemented through outreach work in low-threshold facilities 
such as drop-in centres, drug consumption rooms and centres for social addiction care. 
Mainline plays an important role in monitoring drug use trends and patterns. The information 
generated through its outreach work forms the core of the data received by the Ministry of 
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Monitoring
Monitoring is the regular collection of information which is linked to the 
progress of a project and all its activities. Regular monitoring indicates 
whether things are going as planned and supports project managers in 
acting quickly when something goes wrong. 
Monitoring is an ongoing activity and should be incorporated as such. It 
is normally carried out by CSOs themselves. Simple tools can support the 
collection of information and can directly provide guidance to the project 
manager. 
Evaluation
Evaluation provides information on the intended and unintended effects 
of an intervention. Some questions to be considered on an evaluation can 
be: Has the intervention achieved its planned results? What has changed? 
If the intervention was successful, why did it work so well? If the intervention 
was not successful, what was the cause? What could have been improved? 
Evaluation keeps track of the outcomes and the impact of an intervention 
and informs whether project aims and objectives have been achieved. 
Evaluation is organised at regular intervals during the intervention, mostly 
starting with a baseline assessment to have information on the situation 
at the beginning of the intervention. Follow-up evaluation needs to be 
planned to collect information and to compare relevant changes during 
the lifetime of a project. 
Health. From 2017 on, Mainline and the Ministry have developed a new way of exchange. 
The support to the harm reduction field and its strategies  by the Dutch Ministry of Health 
has resulted in identifying and addressing new drugs and drug consumption patterns. 
Through this collaboration with Mainline, information regarding potential health risks has 
been identified. 
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Involvement of experts and other stakeholders 
Evaluation can also be carried out by external evaluators or in cooperation 
with external stakeholders. External evaluators might have more knowledge 
and expertise with regard to evaluation techniques, but due to financial 
limitation most CSOs won’t be able to hire such kinds of experts. 
The evaluation can also be done by staff members and with additional 
involvement of other stakeholders, such as peers and service users. This 
has advantages as well. It builds their capacities and skills, increases their 
involvement and commitment, and provides more inside knowledge and 
information for the evaluation. 
CSOs need to provide training and support for staff and community 
workers and to ensure that all required resources are available. Evaluation 
plans and tools for monitoring and evaluation should be developed in 
cooperation with all involved stakeholders. 
Challenges
Most CSOs are practice-oriented and, as such, are not necessarily 
experienced in monitoring and evaluation. However, there is an increasing 
demand to report and document on the progress and the impact of their 
work. Funding agencies and governments want to know how the funding 
has been spent and whether project aims and objectives have been 
achieved. It is therefore essential that CSOs build their capacities with 
regard to monitoring and evaluation.
CSOs should also be realistic. Based on limited resources, they will not be 
able to carry out an evaluation which measures up to the highest scientific 
standards. It will not always be possible to carry out an extensive impact 
evaluation. Showing the results of an intervention can already prove 
that things have changed for the better and that pre-defined goals and 
objectives have been achieved. 
Based on existing resources and toolboxes, CSOs should develop their 
monitoring and evaluation strategy and the tools which will be used. To 
make sure that these will be used correctly by staff and peers they need to 
be feasible, practical, and to  add value. 
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Some CSOs might also have ideological reasons for not collecting 
information. This applies in particular to countries in which PWUD are 
strongly marginalised or criminalised. It goes without saying that CSOs 
need to make sure that their documentation and reporting will not be used 
to further exclude their target group. At the same time, there might be 
ways in which monitoring and evaluation can support certain advocacy 
activities without jeopardizing their already tenuous position. 
Relevant components of a monitoring and evaluation strategy 
Define the intervention
Before an evaluation commences it is essential to identify the main 
characteristics of the intervention or project, including: 
 • the target group;
 • the target problem;
 • the purpose of the intervention.
The more specific these characteristics are described, the better. For 
example, ‘providing harm reductions service to drug users’ is quite 
unspecific. If you describe the target group more in detail (e.g. ‘young 
homeless drug users in the centre of Amsterdam’) you already specify 
your target group more. Then, tt will be easier to measure whether an 
intervention has worked or not. 
Define the indicators 
After having defined the intervention you should develop an Evaluation 
Plan. This plan describes how you will implement the evaluation and 
which tools will be used. Relevant elements within an evaluation plan are 
indicators. Indicators are a specific method to describe the aims of your 
intervention. Indicators operationalise aims and make them measurable. 
The indicators should be developed by using the SMART criteria: 
 • S = Specific. What exactly is the objective of the intervention? 
 • M = Measurable. How can you measure  the achievement of your 
 objective? 
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 • A = Achievable. Can you reach your objective with the given 
 resources and within the specific time-frame?
 • R = Relevant. Does the achievement of the objective makes a 
 difference and is it in line with the CSO’s overall goals?  
 • T = Time bound. When does the intervention begins and ends?
In addition to the SMART methodology, it can be helpful to specify the 
quantitative and qualitative elements in your intervention38.
Define sources for the collection of information 
Once the indicators of the intervention are specified, it is important to 
define which kinds of information needs to be collected and which sources 
should be used. These can include: 
 • existing information from statistics, reports and literature;
 • project based information, such as number of clients reached and 
 documentation of performed work; 
 • information from the field through interviews with stakeholders, 
 focus groups and client satisfaction analysis.
Define evaluation methods
An important element within the evaluation is the definition of the methods 
and tools which are used to measure and evaluate progress. These can be 
quantitative (e.g. survey questionnaires) and/or qualitative methods (e.g. 
interviews, focus groups). The evaluation methodology should be clearly 
linked to the defined indicators. The use of different methods, or data 
triangulation,  makes an evaluation stronger and can improve its quality.
Define a timeline  
Whilst monitoring is an ongoing process, it is essential to define the timeline 
for an evaluation. This usually starts with a baseline assessment, but should 
be followed up on a regular basis. A final evaluation moment should also 
be defined to assess whether the intervention has achieved its aims and 
objectives.   38 Horstmann, R. (2002). 
Monitoring and evaluation 
of sexual and reproductive 
health interventions. 
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Use existing guidelines and tools 
There are numerous guidelines and toolkits which can support your 
monitoring and evaluation activities. For more information, check the 
following examples: 
 • EMCDDA (2001) – Guidelines for the evaluation of outreach work: a 
 manual for practitioners39; 
  EMCDDA (2012) - Guidelines for the evaluation of drug prevention: 
 a manual for programme planners and evaluators 
  (second edition)40; 
 • EMCDDA (2010) - Prevention and Evaluation Resources Kit (PERK)41; 
 • EMCDDA - Evaluation Instruments Bank42; 
 • WHO Toolkit for monitoring and evaluation of interventions for 
 sex workers43, 44; 
3.9 Developing action and advocacy plans
The development of a realistic and specific action plan is essential for the 
success of an advocacy strategy. It will help CSOs to plan strategically and 
to organise their work in a feasible way. 
The most relevant components of such an action plan include: 
 • Situation and problem analysis. The situation analysis describes the 
 context and the problem which needs to be addressed by being 
 as specific as possible. A clear focus on a certain group or problem 
 will strengthen your case and make it easier to succeed; 
 • Stakeholder analysis. The stakeholder analysis will indicate with 
 whom you can or should cooperate. It indicates which stakeholders 
 are relevant in the field. Who is an ally? Who is an opponent? Which 
 policy makers and decision makers need to be addressed? Try to 
 include personal names instead of only institutions and organisations. 
 Some relevant stakeholders might have personal preferences and 
 by using this knowledge, CSOs can become more influential;
39Available at: 
http://www.emcdda.
europa.eu/system/
files/publications/221/
Manual2_64382.pdf
40Available at: 
http://www.emcdda.
europa.eu/attachements.
cfm/att_184810_EN_188138_
EMCDDA_Guidelines.pdf
41Available at: 
http://www.emcdda.europa.
eu/attachements.cfm/
att_105843_EN_Manual4 
PERK.pdf
42Available at: 
http://www.emcdda.europa.
eu/eib
43Available at: 
http://www.wpro.who.
int/hiv/documents/docs/
mandetoolkitweb.pdf
44Available at: 
http://correlation-net.org/
images/stories/pdfs/products_
corr3/evaluation_guide_ 
web.pdf
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 • Challenges and bottlenecks. By defining potential bottlenecks and 
 challenges, CSOs can prepare themselves to potential stumbling 
 blocks and to develop alternative plans; 
 • Aims and objectives. The definition of aims and objectives is 
 essential to prepare related actions. Being as specific as possible 
 will help you to make the actions concrete; 
 • Description of the action. The actions and activities are directly 
 linked to the problem analysis and the aims and objectives. The 
 activities operationalise the aims and objectives and help to 
 organise the work flow; 
 • Timeline. The action plan should include a clear timeline which 
 is linked to the activities and indicates a clear start and end of the 
 action. The timeline should include relevant evaluation moments 
 as well.
There are many tools and resources which can help CSOs to develop an 
action plan. For more information please check the following examples:  
 • Community Toolbox: Developing an Action Plan45;
  Mind Tools: Action Plans46;
  Act 2015! UNAIDS Advocacy Strategy Toolkit47; 
 • CIVICUS Advocacy Toolkit: Influencing the post 2015 Development 
 Agenda48; 
 • Open Forum for CSO Development Effectiveness: Advocacy Toolkit 
 - Guidance on how to advocate for a more enabling environment 
 for civil society in your context49; Sustainable Development 2015: 
 Advocacy Toolkit Mini-Site50.
45 Available at:  
https://ctb.ku.edu/en/table-of-
contents/structure/strategic-
planning/develop-action-plans/main 
46Available at: 
https://ctb.ku.edu/en/table-of-contents/ 
structure/strategic-planning/develop-action-plans/main
47Available at: 
http://www.unaids.org/sites/default/files/ 
media_asset/advocacy_toolkit_en_0.pdf
48 Available at: 
https://civicus.org/images/stories/ 
SD2015%20Post-2015%20Advocacy%20Toolkit_FINAL.pdf
49 Available at: 
http://www.civicspace.eu/wp-content/uploads/2017/10/
120110-of-advocacy_toolkit-en-web-2.pdf
50 Available at: 
http://www.sustainabledevelopment2015.org/AdvocacyToolkit/index.php/post-
2015-what-it-is-and-how-you-engage-2/steps-to-develop-your-advocacy-strategy
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This Road Map has set out to provide a resource for civil society organisa-
tions and policy makers as they work towards ensuring that their country is 
leveraging CSO participation in a structured way, that is informed by the 
available evidence and leads to better development, implementation 
and acceptance of drug policies. 
In essence, the Road Map recommends two main things. First, an assess-
ment of the level of CSI as things stand. Second, and informed by the as-
sessment process, a structured approach to improving areas which need 
attention, with agreed actions carried out by policy makers and CSOs ac-
cordingly. 
It is hoped that this resource will be of use to CSOs and policy makers as 
they work towards better drug policies in their countries. A copy of this re-
port, along with a number of additional resources, are available online at 
the project website: www.csidp.ie
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